Dr Fisher is a general cardiologist with experience in echocardiography and angiography. She has a special interest in heart failure, disease prevention and teaching and is passionate about developing equitable care for all heart failure patients. As clinical lead for Northland DHB cardiology, and the current chair of the Cardiac Society Heart Failure working group, she has had input into local heart failure care pathways.
Presented by cardiologist Dr Raewyn Fisher, this recorded webinar explores:
More information on the changes to cilazapril funding and alternative treatment options is available at:
This video was recorded from a live webinar hosted by He Ako Hiringa on 12 August 2021. The video has been edited for clarity.
This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for continuing professional development purposes (1 credit per learning hour). To claim your CPD credits, log in to your Te Whanake dashboard and record these activities under the appropriate learning category.
Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated. ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.
Read the HAH Bulletin to find out more.